Welcome to our dedicated page for Baird Medical Investment Holdings Ordinary Share news (Ticker: BDMD), a resource for investors and traders seeking the latest updates and insights on Baird Medical Investment Holdings Ordinary Share stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Baird Medical Investment Holdings Ordinary Share's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Baird Medical Investment Holdings Ordinary Share's position in the market.
Baird Medical Investment Holdings (NASDAQ: BDMD), a leading developer of microwave ablation (MWA) medical devices, announced its participation in the American Thyroid Association (ATA) Annual Meeting from October 30 to November 3, 2024, in Chicago. The company will showcase its innovations at Booth 100 and host an Expo Theater Presentation on November 2, titled 'Latest Advancements in MWA for Thyroid Treatment'.
The presentation will feature experts from Tulane University, Sun Yat-sen University, and Houston Methodist Hospital. Baird Medical's participation highlights its expansion into the U.S. market following FDA clearance for its MWA technology, offering a minimally invasive alternative to thyroidectomy for benign thyroid tumors. With over 150,000 thyroidectomies performed annually in the U.S., Baird Medical's technology presents a safer option for patients.
Baird Medical Investment Holdings (NASDAQ: BDMD) announced preliminary financial results for the six months ended June 30, 2024. Total revenues increased by 13.8% year-over-year to US$13.1 million. Gross profit rose 20.9% to US$11.5 million, while operating income grew 70.0% to US$5.1 million. Net income saw a significant increase of 85.8% to US$4.4 million.
CEO Haimei Wu highlighted the company's strong performance in China and initial traction in the U.S. market following FDA clearances. Baird Medical aims to expand in the U.S., offering minimally invasive microwave ablation technology as an alternative to traditional thyroidectomy for benign thyroid tumors. The company recently completed a business combination with ExcelFin Acquisition Corp. and began trading on Nasdaq under the ticker symbol BDMD on October 2, 2024.
Baird Medical Investment Holdings (NASDAQ: BDMD) has successfully listed on the Nasdaq exchange, marking its transition to a public company. The company, a leading microwave ablation (MWA) medical device developer in China, began trading under the ticker symbol 'BDMD' on October 2, 2024. This milestone follows Baird Medical's recent expansion into the U.S. market after receiving FDA 510(k) clearances.
Co-Founder Wenyuan Wu rang the Opening Bell to celebrate the occasion. The company's technology offers a minimally invasive alternative to thyroidectomy for patients with benign thyroid tumors, addressing a significant market need in the U.S., where 150,000 thyroidectomies are performed annually. Baird Medical's MWA technology aims to provide safer and more efficient procedures for thyroid care, benefiting both patients and physicians.
Baird Medical Investment Holdings (NASDAQ: BDMD), a leading microwave ablation (MWA) medical device developer and provider in China, has announced its participation in Roth's 3rd Annual Healthcare Opportunities Conference on October 9, 2024, in New York City. The company's management plans to host one-on-one and small group meetings with institutional investors at the event.
This participation comes as Baird Medical expands its footprint in the U.S. market following recent FDA clearance for its minimally invasive microwave ablation technology. The company's technology offers a promising alternative to thyroidectomy for patients with benign thyroid tumors. Currently, 150,000 thyroidectomies are performed annually in the United States.
Baird Medical's expansion into the U.S. market follows its receipt of US FDA 510(k) clearances, positioning the company to tap into a significant market opportunity in thyroid tumor treatment.
FAQ
What is the current stock price of Baird Medical Investment Holdings Ordinary Share (BDMD)?
What is the market cap of Baird Medical Investment Holdings Ordinary Share (BDMD)?
